Mylan N.V. said the UK’s High Court of Justice issued a decision in favor of Mylan and its European partner Synthon “finding all claims of Teva’s patent EP (UK) 2 949 335 (EP 335) relating to Copaxone 40 mg/mL invalid based on obviousness.”
Copaxone is Teva’s blockbuster multiple sclerosis treatment.
“This victory is yet another important milestone for Mylan, and this U.K. court decision only further increases Mylan’s confidence in its ability to bring high quality, lower-cost generic versions of Copaxone to the multiple sclerosis community and patients around the world,” said Mylan.
“Over the course of the last eight years, Mylan has successfully overcome Teva’s four waves of U.S. patent litigation, eight Citizen Petitions, injunction proceedings in India, more than 15 regulatory challenges, patent litigations or commercial actions across Europe, and now the litigation in the U.K., in addition to obtaining dismissal of Teva’s suit against the FDA seeking to delay approval of the 20 mg/mL product.
“Today’s positive ruling in the U.K. will further help pave the way for Mylan’s future launches of Glatiramer Acetate Injection 40 mg/mL in certain European markets.”